We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


IntegraGen announces €2 million Equity Investment and R&D partnership with DSM Personalized Nutrition Group

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "IntegraGen announces €2 million Equity Investment and R&D partnership with DSM Personalized Nutrition Group"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

IntegraGen has announced that DSM Venturing, the corporate venturing arm of Royal DSM N.V. has invested €2M in the Company.

In addition, it has entered into a collaborative R&D partnership with the DSM Personalized Nutrition Group for the development of molecular diagnostic products for personalized healthcare.

IntegraGen is focused on the development of diagnostic and prognostic genetic tests for a range of complex diseases using its proprietary technology platform for gene identification (Genome HIP™).

Under the terms of the agreement with DSM, the Company will receive upfront fees, license fees and funding for research and development.

In addition, IntegraGen will be eligible for royalties upon commercialization. Each company will retain rights to the intellectual property portfolio developed under the collaboration in their areas of focus, being diagnostics and medicines for IntegraGen and nutrition for DSM.

Dr Jan Mous, President and CEO of IntegraGen, said: “The DSM collaboration enhances our position in the personalized medicine market, promising to further expand our patent portfolio and commercialized products in the areas of obesity and metabolic disorders. 

The DSM relationship is a testimonial to the value of IntegraGen’s intellectual property and capabilities for identifying genes of interest to IntegraGen and partners in the diagnostics and personalized healthcare markets.”

DSM found in IntegraGen a partner with world-class capabilities in personalized medicine. DSM has not only recognised the Company’s first-class research capability and access to targeted patient collections, but also the unparalleled competitive advantage of its technology, Genome HIP™, which provides the ability to rapidly identify genes associated with any complex genetic disorders, such as obesity and type 2 diabetes.

Rob van Leen, Chief Innovation Officer at DSM said: “We recognize that IntegraGen’s innovative and pioneering technologies in the field of personalized healthcare have applications across the full spectrum of healthcare from medical treatment to lifestyle management.

We are delighted to enter into a partnership with a company with such a powerful technology, which, associated with IntegraGen’s expertise in the medical/pharma application of personalized healthcare, will allow us to rapidly realise the commercial potential of our weight management programmes, an important area within the emerging field of Personalized Nutrition.”